NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial ...
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX100 On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback